Multiple groups reported progress in in vivo gene‑editing and delivery in 2025, pushing the modality toward broader clinical translation. New strategies addressed tissue targeting, payload delivery and immunogenicity, and firms disclosed preclinical programs that overcame historic barriers to in vivo efficacy. These cumulative advances—reported across academic journals and industry announcements—signal a turning point for therapies designed to edit or replace genes directly inside patients, although translational and safety hurdles remain.